BRIM BIOTECHNOLOGY

Our lead asset, BRM421, is on track to become a first-in-class treatment for dry eye disease (DED) which treats and repairs cornea damage. BRM421 has demonstrated safety and efficacy in two clinical studies. BRIM is devoted to expanding this synthetic peptide's indications, including treatments for neurotrophic keratitis (BRM42 4), and osteoarthritis (BRM521)... BRIM Biotechnology applies integrated and efficient translational science to develop new treatments that help combat and cure disease. The company was founded in August 2013 in Taiwan by a team of seasoned, entrepreneurial global pharma experts. We believe medicines with the potential to cure disease, or significantly improve patient lives, should be affordable to health systems and accessible to patients worldwide... BRIM's extensive experience and successful track record of translating discovery research to the clinic enables us to identify and incubate high-potential novel drug candidates through our unique drug..

Also known as: BRIM Biotechnology, Inc.

Primary location: Taipei Taiwan